» Articles » PMID: 15304589

Immediate Post-radiotherapy Changes in Malignant Glioma Can Mimic Tumor Progression

Overview
Journal Neurology
Specialty Neurology
Date 2004 Aug 12
PMID 15304589
Citations 156
Authors
Affiliations
Soon will be listed here.
Abstract

To determine the frequency of progressive MRI lesions shortly after radiotherapy for glioma with spontaneous improvement or stabilization, the authors studied a cohort of patients treated within two prospective phase III trials with radiotherapy only. In 9 out of 32 patients, the first post-radiotherapy MRI showed progressive enhancement. In 3 of these 9 the MRI improved or stabilized for 6 months without additional treatment. The authors conclude that patients with progressive lesions within 3 months after radiotherapy should not be eligible for phase II trials on recurrent glioma.

Citing Articles

Advances in Glioblastoma Diagnosis: Integrating Genetics, Noninvasive Sampling, and Advanced Imaging.

Gough R, Treffy R, Krucoff M, Desai R Cancers (Basel). 2025; 17(1.

PMID: 39796751 PMC: 11720166. DOI: 10.3390/cancers17010124.


T2-FLAIR imaging-based radiomic features for predicting early postoperative recurrence of grade II gliomas.

Wang Z, Shu J, Feng L Future Oncol. 2024; 20(35):2757-2764.

PMID: 39268928 PMC: 11572138. DOI: 10.1080/14796694.2024.2397327.


Extracellular vesicles in glioblastoma: a challenge and an opportunity.

Indira Chandran V, Gopala S, Venkat E, Kjolby M, Nejsum P NPJ Precis Oncol. 2024; 8(1):103.

PMID: 38760427 PMC: 11101656. DOI: 10.1038/s41698-024-00600-2.


Short-term predictors of stereotactic radiosurgery outcome for untreated single non-small cell lung cancer brain metastases: a restrospective cohort study.

Neto E, de Almeida Bastos D, Yoshikawa M, Figueiredo E, Souza Filho F, Prabhu S Neurosurg Rev. 2024; 47(1):172.

PMID: 38639882 DOI: 10.1007/s10143-024-02415-y.


Brain Re-Irradiation Or Chemotherapy: a phase II randomised trial of re-irradiation and chemotherapy in patients with recurrent glioblastoma (BRIOChe) - protocol for a multi-centre open-label randomised trial.

Hudson E, Noutch S, Webster J, Brown S, Boele F, Al-Salihi O BMJ Open. 2024; 14(3):e078926.

PMID: 38458809 PMC: 11145639. DOI: 10.1136/bmjopen-2023-078926.